Imbrium Therapeutics Files IND For Sunobinop In Alcohol Use Disorder
05 Aug 2024 //
BUSINESSWIRE
Imbrium Completes Clinical Trial For Overactive Bladder Treatment
09 Jul 2024 //
BUSINESSWIRE
Imbrium Completes First Patient Visit in Ph1 Study of Potential Treatment
20 Dec 2022 //
BUSINESSWIRE
Imbrium Therapeutics Presents Results of a Phase 2 Study of Sunobinop
12 Dec 2022 //
BUSINESSWIRE
Purdue subsidiary buys non-opioid pain prospect
12 Aug 2021 //
FIERCEBIOTECH
Imbrium Presents First Data and Describes Novel Mechanism of Action For IMB-115
28 Aug 2020 //
MARKETS
Imbrium Therapeutics L.P Announce 1st Patient Dosed in Phase 1/2 Clinical Study
26 Nov 2019 //
BUSINESS WIRE